Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS

Kadimastem Approaches Final Steps for Securing Merger Completion

ZURICH and NESS ZIONA, Israel, Jan. 16, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous system disorders, and Kadimastem Ltd. ("Kadimastem") (TASE: KDST), a clinical-stage cell therapy company developing and manufacturing "off-the-shelf" allogeneic cell products for the treatment of neurodegenerative diseases and potential cure of diabetes, announces that Kadimastem has issued a notice to convene a special general meeting of Kadimastem's shareholders to approve the merger transaction with NLS. The Central District Court in Israel has approved that this meeting may occur within a reduced time frame of only 14 days from the date of publication of the meeting notice. This meeting is needed to secure Kadimastem's shareholder approval which are critical to completing the merger process.

Read more at prnewswire.com